That is what I saw to , maybe only time will tell . Thanks for your take . GLTUA

Need alittle help from the doc's here , ran acroos this while looking into Shirley Ryan AbilityLab that is doing the two stage Phase 2A and 2B clinical study for RSPI. Kinda interesting that both companies are there at the same time. Any feedback or thoughts would be welcomed
https://nervgen.com/nervgen-pharma-provides-update-on-phase-1b-2a-clinical-trial-of-nvg-291-in-spinal-cord-injury/

https://www.sciencedirect.com/science/article/pii/S002839082400279X

No problem , i was just asking was that from 2019

Thats from the deal in 2019 correct

When communicating with Jeff CEO and Paul from the investor agent , My point blank question was if they were investors looking would they invest in RSPI based on the last 6 months and the actions they have showed is it a good look. No replie on answering it directly but both noted it is a concern they hope to explain and direction forward in the letter
IMO I think they are waiting on a few more goals and positive reults and then we see what this company will be going forward.
Stay safe for all that are in the weather storm forecast for the next couple of days , and positive thoughts for the fire victims GLTA

Yes look at this one , over the past 1 year. flying high then a bad result . SYRS Syros Pharmaceuticals Inc , I think the right results and news we could see SP in the dollars. This company doesnt have what we have been told RSPI has at look at their SP even today. Jeff was saying he was getting there , and was trying to explain everything good bad and what they have challeging left to get over and gives us what they want to get done in 2025. Hopefully they do have BP lined up and maybe it is a Buyout and the main players are kept on and running the show. Who knows GLTA

AI Overview
Learn more
The outlook for KRM-II-81 under RespireRx appears positive, with preclinical studies showing promising potential as a novel treatment for pharmacoresistant epilepsy due to its ability to suppress epileptiform activity in brain slices from patients with treatment-resistant epilepsy, alongside demonstrating significant analgesic effects with minimal side effects like sedation or tolerance development, making it a potential new drug for managing severe pain conditions as well.
Key points about KRM-II-81:
Mechanism of Action:
KRM-II-81 acts as a positive allosteric modulator of the a2/3-containing GABA receptor, enhancing its activity and leading to increased inhibitory neurotransmission, which could be beneficial in managing seizures and pain.
Preclinical efficacy:
Studies in animal models of pharmacoresistant epilepsy have shown KRM-II-81 to be effective in suppressing seizures with minimal side effects compared to standard antiepileptic drugs.
Patient tissue studies:
Research has demonstrated KRM-II-81's ability to suppress hyperactivity in cortical slices from patients with pharmacoresistant epilepsy, further supporting its potential clinical translation.
Pain management potential:
Preclinical data also indicates KRM-II-81's analgesic properties, showing significant pain relief without the associated risks of opioid dependence or respiratory depression.
Potential challenges:
Clinical trials needed:
While preclinical results are promising, further clinical trials are required to confirm efficacy and safety in human patients.
Regulatory pathway:
Navigating the regulatory process for a new drug can be complex and time-consuming.
Overall, KRM-II-81 under RespireRx holds significant potential as a new treatment option for patients with pharmacoresistant epilepsy and potentially other pain conditions based on its preclinical data demonstrating potent anti-seizure and analgesic effects with a favorable safety profile.
Structural Analogs of the GABAkine KRM-II-81 Are Orally ...
Laboratory of Antiepileptic Drug Discovery, St. ... KRM-II-81 is active in models predicting efficacy in pharmacoresistant epileps...
National Institutes of Health (NIH) (.gov)
RespireRx Pharmaceuticals Inc. Announces Publication of ...
Nov 30, 2021 — (OTCQB: RSPI) (“RespireRx” or the “Company”), is pleased to announce that scientists associated with the Company have ...

BioSpace
RespireRx Pharmaceuticals Inc. Announces a Department of ...
May 29, 2024 — In support of its potential clinical efficacy, translational studies have demonstrated the ability of KRM- II-81 to dr...

RespireRx
Show all
Generative AI is experimental.

Letter is not to far off , will address comments / concerns , the good and bad of 2024 , 2025 plans , ect.. should be an informational letter. GLTA

No problem , Hopefully he follows thru for all of us to get new info. When talking to Jeff and the funding company Paul I simply ask the question if you see what is going on the info pack that you pass on to review is nothing more than the past news that all of us have already seen what makes you think this is going to bring in new investors. Paul states they are going to tallk again with RSPI and always offers to setup communications with Jeff . They really need updated material if they are looking to bring in new investors or any of us to buy into the blocks of perfered shares. IMO Hopefully they have things in motion and we will be updated soon. GLTA

I guess since you may have ten shares you don't have a concern of what is and isn't happening. All we are all asking is to give the investors the news they said they would and follow thru on what they say they will do . Sorry you dont understand what we all but you are looking from RSPI. Thanks for you input I have awarded you the Ignore award of the day . Everyone no problem we are all just searching for the clues and news as we get it. Hopefully Jeff follows thru and there is new news and not a lot of recycle info with no updates. Have a great weekend

You worry about your investment your way and I will take care of mine my way.

As I have indicated in prior discussions, we intend to issue a comprehensive letter to shareholders and other stakeholders and we are currently working on it (along with many other things). We do expect to issue it shortly.



Sincerely,



Jeff

Email I just sent off
Hey Jeff everyone is asking about the shareholders letter. Not to kick a dead horse but as I pointed out to Paul handling the overseas funding , how does a future investor feel good about the lack of updates and the appearance that RSPI has been displaying for the last 6 months. Being on the EM we all that have invested are kinda stuck and lacking updates or news just makes us all have concerns of what is going on. Hope to get a good reply that can be posted or related to the investors . Thank you for your time and efforts

It took awhile , but it is where it was almost when the R/S took place . Koos and his scams
This phrase refers to a legal document, specifically "Form 15" filed with the Securities and Exchange Commission (SEC), which essentially signifies a company's certification that it is terminating its registration of a class of securities under Section 12(g) of the Securities Exchange Act of 1934, meaning they no longer need to file periodic reports because they have become a private company, or that they are suspending their duty to file reports under Sections 13 and 15(d) of the same act; effectively removing their public reporting obligations.
Key points about this phrase:
Form 15: This is the official SEC form used to make this notification.
Section 12(g): This section of the Securities Exchange Act outlines the requirements for a company to register its securities with the SEC and become subject to periodic reporting.
Sections 13 and 15(d): These sections dictate the specific reporting requirements that a public company must follow.
When a company might file this form:
When the number of shareholders of a publicly traded class of securities falls below a certain threshold, allowing them to "go private".
If a company is undergoing a merger or acquisition that results in a significant reduction in public shareholders.

Yes when talking about investing in it , it is clear it is seprate. I have asked many times about any updates and the look the entire company has presented for over 6 months and it really isn't the look an investor is looking for. They always offer to setup a call with Jeff to answer questions, and I tell them we have talked to Jeff and nothing is cleared up , nothing new is offered and no follow thru has taking place. They then offer to set something up, I dont think they get that talking is not getting anything positive out , it instead is keeping us all in the dark about where the company is currently and has been for 6+ months. The whole time the cost of getting current keeps increasing as it was presented to me about needing 100+150k to the last statement of 200+250k. GLTA

Here is what I just got from the funding investment group handling the sub company . The replie below was to the posting I sent them by All City Baby

Re: LTListener post# 52589

I agree that the current state of the website is quite awful. Not only does it look amateurish, on the company management page it lists Dr. James Manuso as the CEO. He left the company on September 30, 2018.

https://www.respirerx.com/corporate/management.html

https://www.globenewswire.com/news-release/2018/06/19/1526825/0/en/RespireRx-Pharmaceuticals-Inc-Announces-Resignation-of-Dr-James-S-Manuso.html

Happy new year to you too. Thanks for your email.


Maybe check your sources regarding the management page on the company’s website. Link below for your reference.

https://respirerx.com/scientific-team-leaders/

Whilst I appreciate the information you have provided, as previously mentioned I’m assisting with raising capital for ResolutionRX so this is where I’m spending my efforts. If you have queries / concerns, or require information for RespireRX, as you are a shareholder, I kindly suggest you speaking with Jeff Margolis directly

It takes more than they currently are at. Only way is a merger at this point would be the quickest , I also wrote Jeff he was on the road and will get back with me , I asked him about letter. I also wrote the investment firm and passed on some of our concerns and pointed out what we all are seeing and feeling and with no info or updates how do they think they will raise funding for RSPI. He was out of office til the 6th so hopefully he will present our concerns to RSPI and ask the same questions we are all concerned about.

https://listingcenter.nasdaq.com/assets/initialguide.pdf

https://www.nasdaq.com/solutions/listings/markets/americas/ways-to-list

Just wrote Jeff asking if anything new that could be reported and if he was still working on shareholders news letter. We will see what happens

https://blog.otcmarkets.com/2021/03/25/understanding-the-expert-market/

Do we see a shareholders letter before or after the 1st of year

Merry Christmas to all .

So what is your take a good thing or bad thing for RSPI

I think that was a mic drop

Thank you

When you have gone live will you post the link , I dont have any of the social media as accounts , I will be willing to sign up . Thank you

Maybe , I also asked Jeff about that and posted that reply. Very weird when it is linked to RSPI . Time will tell

Maybe more info here I didnt sign up for it yet
https://synapse.patsnap.com/drug/8352d5be6aed4348805cfb3f7484d899

https://synapse.patsnap.com/drug/8352d5be6aed4348805cfb3f7484d899

Somebody in the Great white north or who can buy on the EM could drive this up at anytime. My understanding of the trading on EM if two matching bid and ask is there it sells, could be wrong but if true someone could put a 100 shares up for .10 and someone could match it and we would be looking good. That would be a nice sight.

Hopefully RSPI gets a great XMAS present in the form of investor funding or a play by BP. Just a matter of time now .

Hopefully the news letter he will put out isnt a rehash of already known info , but is all new and with a direction and a plan in place. GLTA

Here is what I got today from the investor group I posted awhile back and my reply . The reply he sent contains basically same info I posted awhile back that Jeff had talked about.
Hi XXXX,
Trust all is well.
I caught up with the company last week to press them on their SEC filings. Please find their response below
“With respect to getting current with our SEC filings, we would require approximately $150,000 and it would take approximately two month (subject to staff availability at our auditors) to catch up on the 31 Dec 2023 annual report and three quarterly reports. The $150K would be sufficient for us to complete timely (possibly on extension), the 31 Dec 2024 annual report.”
The company is cash-strapped, hence why it’s taking time to get their filings up to date. Would this be something you could potentially support if there was a meaningful equity component as an incentive?

Please let me know your thoughts.
Best Regards,
XXXX

Thanks I have been in talks with Jeff , I knew of the need for cash.

What I and other investors have concerns is with all the grants they have and positive results that they have released why no big invetsor or Big Pharm hasnt stepped in. The share structure that he was talking about to me just isnt enough to take more of a risk along with no gurantee they would come off EM and not return to it mid year. They could have gone a different direction than the EM , instead they went there, now they have no real way of trading to raise money. Many of us would have rather them have diluted a small amount of shares and stay on the OTC so it could have traded and build up the share price not collapse it on the EM. If we took the class shares he was talking about we would be stuck with shares that we would not be able to sell easily. I already have 15M shares at an average of .00098 and I am holding but to put in a 10k - 25k additional investment is not on my table.

Thanks for your response and have a great holiday season

Long time hope you are doing well
You served it up good with this Over 300 Million in liabilities and we are to believe a lawyer is exactly going to get what for the investors , while this clownass is out of the country. GLTAOU

Hey Doc , what does the lawyers think they will be able to recover. We all know they have no money on the books . So is this more about sending them to jail or shutting them down. What is actually recoverable ? Just asking

Nothing has changed since 2018 all hype no follow thru . Pretty sad they had a great product.

Boy does this sound just like the info we were give over the years . Sounds like the cure speech , where is Enzo the chimp he has had to be cured by now.

1606 Corp. Target for Strategic Investment Adnexus Biotechnologies Merges With Sanctum Therapeutics to Obtain Breakthrough HIV and SARS-CoV-2 Treatments
8:03 AM ET 11/12/24 | Dow Jones

SEATTLE, WA / ACCESSWIRE / November 12, 2024 / 1606 Corp. (OTC PINK:CBDW) (the "Company" or "1606"), a leader in AI technology, acquisition target Adnexus Biotechnologies Inc. is delighted to reveal the completion of a merger agreement to acquire Sanctum Therapeutics core technology assets for treating HIV and SARS-CoV-2. This merger will combine the two biotechnology companies' significant resources and expertise. The combination of resources and expertise significantly enhance the research capabilities of Adnexus's HIV and SARS-CoV-2 research.

Adnexus Biotechnologies Inc. is poised to revolutionize its HIV and infectious disease portfolio with the acquisition of Sanctum Therapeutics' leading-edge assets. This strategic merger combines Adnexus's state-of-the-art AI-driven drug discovery platform with Sanctum's innovative long-acting HIV capsid inhibitor and Adnexus's short-acting anti-HIV monoclonal antibodies. Together, these therapies offer a potent, dual-action approach that enhances treatment efficacy, reduces the risk of viral resistance, and provides a promising new option for HIV patients.

The acquisition further strengthens Adnexus's position in the rapidly growing market for HIV treatments, while also expanding its pipeline of drug candidates targeting antimicrobial-resistant infections and other infectious diseases. With Sanctum's advanced inhibitors and expertise in navigating the FDA regulatory landscape, Adnexus is uniquely positioned to accelerate the development of high-impact therapies.

Austen Lambrecht, CEO of 1606 Corp., commented, "The merger between Adnexus Biotechnologies and Sanctum Therapeutics marks a pivotal moment in the fight against HIV and other infectious diseases. By combining Adnexus's cutting-edge AI-driven drug discovery platform with Sanctum's breakthrough therapies, they are not only advancing the development of life-saving treatments but also driving forward our mission to leverage technological innovation for the betterment of global healthcare. Lambrecht continued, "This strategic partnership underscores our commitment to supporting transformative biotech advancements, and we are excited to play a role in helping bring these therapies to market for those who need them most."

This synergistic combination of resources, along with Adnexus's cutting-edge Sutra AI Drug Discovery Platform, creates a powerful foundation for continued innovation and growth, ultimately delivering significant value for patients and shareholders alike.

Adnexus has recently executed a Letter of Intent with the Company for a strategic investment by the Company for 5% of Adnexus. The LOI terminates on November 27, 2024 and has an option to extend.

About Adnexus Biotechnologies Inc.

Adnexus is a leading innovator in biotechnology, specializing in AI-driven solutions for early drug discovery, infectious disease and neurodegenerative disease research. Its proprietary methods focus on developing therapeutic solutions by leveraging human immune-B cells, offering a cutting-edge approach to creating highly effective treatments. For more information, please visit https://www.adnexusbiotech.com.

Hey doc where do you sign up , has that happened yet . count me in

You havent block him yet .

Yes it will be nice to get off the EM .

I can sell you 640k at .02 if you would like

Thank you for the effort. The concerns are legitimate.
In response to 1 and 2.
One of the ways we addressed the concern about the EM and possibly going back to the EM if inadequate funds were raised was by creating a security that is not dependent upon the stock to be trading for it to pay off. That was our Series I Preferred Stock that pays off if a strategic deal struck ($15mm or more in any consecutive 12 month period that need not be a calendar year) regardless if the common stock is trading or not. We recently enlarged the available Series I stock to accommodate up to $200,000 of additional investment by amending the certificate of designation with Delaware and then filing an 8-K on September 6, 2024. The way it works, and while the preferred stock is not convertible to common, we value it on a hypothetical common share basis at $0.0015/share. Then, when a strategic deal takes place that meets the criteria, the payout is at $0.02 per share. A $25K investment pays off a gross amount of ($25,000/$0.0015)x$0.02 or $333,333 for a profit of $308,333 or 12x profit. The stock does not need to be trading for the payoff to happen. I believe you have been reading our prior SEC filings, so you will be aware that we had previously sold for or used Series I to pay off liabilities for an aggregate of $245,000 and we enlarged it to accommodate up to an additional $200K. But you would have to believe we would do a strategic deal that yields $15mm in any consecutive 12 month period.
Here is the link to the 8-K itself and then the link for the actual amendment which is an exhibit to the 8-K.
https://www.sec.gov/Archives/edgar/data/849636/000149315224035221/form8-k.htm
https://www.sec.gov/Archives/edgar/data/849636/000149315224035221/ex3-1.htm
A summary of the Series I is attached that was written shortly before the actual amendment was filed in Delaware and with the SEC.
The investors we have that are interested in the Series I, are individually not of sufficient size to close. They would close if the closing was $150K or more.
In response to 3.
We have had and continue to engage with biotechs, biopharma and big pharma episodically. Eventually, we anticipate getting a deal done in one asset category or another. I personally exchanged $210,000 of accrued unpaid compensation for Series J preferred stock (other executives have exchanged as well) which is less lucrative terms than the Series I and would be harder to hit the threshold as the threshold for Series J is $20 million, $5mm higher than the threshold for Series I.
No response necessary for your point 4. It would take a lot of common which would be highly dilutive to existing shareholders like yoursel

Hello
Thanks everyone seems to have the same concerns . Here are the major and from what I am getting as feedback most will not take that risk due to the cornerns of whay the EM happened in the first place .


1) Major concern is that they invest and then 2qrt comes and their is no money and RSPI is back to the same sisutation they are in now (AKA) EM
2) If you have other investors why this hasn't been resolved
3) With everything going on , why BP or major backers stepped up for merger or buyout yet.
4) It would take atleast 50m shares for a 10m investment for them
Thank you for your time , I still hold my shares and support your research and believe you will help the millions who suffer everyday .